GENERATION_TO_PI_OUTPUT

Cycle ID: 2

Hypotheses generated:
- Axis1_AMD1_immune
- Axis2_AMD1_vascular
- Axis3_AMD1_EV
- Axis4_Inosine_immune
- Axis5_Inosine_vascular
- Axis6_Matricellular_exploratory

All hypotheses below are anchored to the mandatory metabolomics‑to‑mechanism evidence chain (differential metabolite → KEGG enzyme/pathway‑neighbor gene → MK expression/PH shift → directional downstream biology → vascular remodeling phenotype). They keep downstream axes provisional, do not over‑resolve specific cell subsets or mediators, and include falsification criteria.

---

### Hypothesis ID: Axis1_AMD1_immune
**Hypothesis title:** MK AMD1‑polyamine axis configures a pro‑remodeling perivascular immune environment.
**PI instruction addressed:** Candidate‑axis validation for Evo_H1 (MK‑AMD1‑polyamine), immune‑mediated route.
**Core directional hypothesis:** Hypoxia upregulates AMD1 in lung megakaryocytes, increasing polyamine production, which modulates local immune cell polarization and promotes pulmonary vascular smooth muscle activation and muscularization.
**Direction‑level reasoning summary:**
- **Data anchor:** Methionine is elevated in PH‑CD41⁺ sorted MKs (log2FC 3.26, sFig6A); *Amd1* is MK‑enriched (log2 1.353) and significantly upregulated under PH (log2FC 1.77, p = 6.55 × 10⁻⁶, Seurat).
- **Biological interpretation:** Methionine elevation with parallel AMD1 induction suggests increased flux through S‑adenosylmethionine (SAM) and diversion into polyamine synthesis, a stress‑responsive metabolic switch.
- **MK‑linked pathway logic:** AMD1 (S‑adenosylmethionine decarboxylase) is the rate‑limiting enzyme for spermidine/spermine biosynthesis; polyamines are small cations that influence cell proliferation, differentiation, and immune cell fates.
- **Candidate downstream axis:** Immune‑mediated (polyamines can alter T‑helper/Th17‑like tone, macrophage phenotype). Direct vascular‑wall and EV/stromal are alternative routes.
- **Remodeling logic:** Altered perivascular immune signals drive smooth muscle cell activation, medial thickening, and vascular stiffness.
- **Key uncertainty:** Whether MK‑derived polyamines reach perivascular immune cells at immunomodulatory concentrations, and whether the net effect is pro‑remodeling.

**Directional chain:**
1. Hypoxia elevates methionine uptake/metabolism and upregulates *Amd1* in lung‑resident MKs.
2. MK AMD1 commits SAM carbon to polyamine (spermidine/spermine) synthesis, creating a concentrated polyamine source.
3. Broad downstream axis: **Immune‑mediated** (polyamines modify perivascular T‑helper/Th17‑like balance, monocyte/macrophage state, or neutrophil responses).
4. Altered immune tone promotes smooth muscle cell hyperplasia and fibroblast activation.
5. Contributes to muscularization and vessel wall stiffening.

**Candidate downstream axes:**
- *Plausible axes:* Immune‑mediated, direct vascular‑wall, EV/stromal, unresolved.
- *Working model (provisional):* Polyamine‑driven skewing of perivascular T‑cell/Th17‑like responses.
- *Specific examples (candidate only):* Spermidine may suppress Treg function or enhance IL‑17‑producing cells; not a settled mechanism.
- *MK‑origin gap:* Distance from lung MKs to perivascular immune niches and polyamine half‑life in tissue.
- *Falsification:* Conditional *Amd1* KO in MKs (Pf4‑Cre) should reduce perivascular T‑cell activation markers and attenuate muscularization; if polyamine inhibition fails to alter immune readouts but still reduces remodeling, the direct vascular axis may dominate.

**Evidence basis:**
- *User‑provided data:* Methionine up in PH MKs (sFig6A); *Amd1* MK enrichment and PH‑up expression (Seurat).
- *Public dataset analysis:* GSE289322 differential expression output (**awaiting review**); if *Amd1* or polyamine pathway genes are upregulated in whole‑lung PH, it would support tissue‑level propagation of the MK‑initiated metabolic shift.
- *Literature:* AMD1 is linked to mTORC1‑driven polyamine metabolism in cancer; polyamines can modulate immune cell differentiation, but no direct PH‑specific literature.
- *Biological rationale:* Methionine salvage and polyamine pathways are evolutionarily conserved stress responses that can rewire local immune environments.
- *Evidence status:* **Direct** for MK metabolite/enzyme; **inferred** for polyamine effect on immunity; **speculative** for bridging MK polyamines to vascular remodeling.

**Predicted observations:**
- *In MKs:* Increased AMD1 protein and polyamine (spermidine/spermine) levels under hypoxia.
- *In recipient or tissue compartment:* Perivascular space shows elevated polyamines (by mass spectrometry imaging) and altered lymphocyte cytokine profiles.
- *In metabolomics/pathway activity:* Whole‑lung polyamine levels correlate with AMD1 expression; GSE289322 GSEA may enrich arginine/proline metabolism (FDR < 0.25) if MK metabolic shift propagates.

**Experimental validation:**
- *Perturbation:* Conditional *Amd1* knockout in MK/platelet lineage (Pf4‑Cre × *Amd1*^fl/fl).
- *Model:* Chronic hypoxia (3 wk) in mice.
- *Readout:* Lung immune cell composition (flow cytometry for T‑cell subsets, macrophages), polyamine tissue measurements, and muscularization (α‑SMA morphometry).
- *Expected result:* *Amd1* KO reduces perivascular T‑cell activation (e.g., down‑modulation of Th17‑associated cytokines) and attenuates muscularization.
- *Falsifying result:* No change in immune cell profiles despite reduced muscularization, or polyamine reduction not accompanied by any remodeling benefit.

**Novelty:** First proposal that MK‑intrinsic polyamine synthesis acts as a paracrine immunomodulator to drive pulmonary vascular remodeling.
**Weaknesses:** No direct evidence that polyamines released by MKs reach immune cells at effective concentrations; immune phenotype is broadly defined.

**Revision relative to previous cycle:** New candidate axis under Evo_H1.

**Priority estimate (1‑5):**
- Directional specificity: 4
- Data support: 4
- Literature support: 3
- Novelty: 5
- Testability: 4
- **Overall generation priority: 4**

---

### Hypothesis ID: Axis2_AMD1_vascular
**Hypothesis title:** MK AMD1‑generated polyamines directly stimulate pulmonary arterial smooth muscle cell proliferation.
**PI instruction addressed:** Candidate‑axis validation for Evo_H1, direct vascular‑wall route.
**Core directional hypothesis:** Hypoxic lung MKs upregulate AMD1, produce spermidine/spermine, and release them onto adjacent PASMCs, driving proliferation and medial muscularization.
**Direction‑level reasoning summary:**
- **Data anchor:** Same methionine‑AMD1 pair (above).
- **Biological interpretation:** Polyamines are classical growth‑promoting compounds for smooth muscle cells; MKs residing near pulmonary vessels could supply mitogenic polyamines.
- **MK‑linked pathway logic:** AMD1‑dependent polyamines sustain cell cycle by stabilizing nucleic acids and regulating ion channels; direct transfer from MK to PASMC is plausible if spatial proximity exists.
- **Candidate downstream axis:** **Direct vascular‑wall** (PASMC hyperplasia, endothelial dysfunction).
- **Remodeling logic:** PASMC proliferation and medial hypertrophy increase wall thickness and vascular resistance.
- **Key uncertainty:** Whether MKs are positioned close enough to deliver polyamines to PASMCs and whether polyamine concentrations reach mitogenic thresholds.

**Directional chain:**
1. Hypoxia → MK *Amd1* up → polyamine (spermidine/spermine) overproduction.
2. MKs release polyamines (secretion, cell lysis, or EV‑mediated) into the perivascular space.
3. Broad downstream axis: **Direct vascular‑wall** — polyamines interact with PASMCs, activating growth‑promoting signals (e.g., mTOR/S6K, ornithine decarboxylase).
4. PASMC proliferation and migration → medial thickening.
5. Contributes to heightened muscularization and pulmonary artery occlusion.

**Candidate downstream axes:**
- *Plausible axes:* Direct vascular‑wall, immune‑mediated, EV/stromal.
- *Working model (provisional):* Polyamines act as paracrine mitogens on PASMCs.
- *Specific examples (candidate):* Spermidine could activate NMDA receptors or eIF5A hypusination in PASMCs; not settled.
- *MK‑origin gap:* Proximity of lung MKs to medial layer and polyamine diffusion efficiency.
- *Falsification:* Conditional *Amd1* KO in MKs should reduce PASMC proliferation (Ki67⁺ cells in media) and medial thickness; if KO lowers polyamines but does not alter PASMC proliferation, the direct vascular axis is unlikely.

**Evidence basis:**
- *User‑provided data:* As above.
- *Public dataset analysis:* GSE289322; if a polyamine‑responsive proliferation signature correlates with *Amd1* in whole lung, it would support the axis. **Awaiting DE results.**
- *Literature:* Polyamines are known smooth muscle cell growth factors in systemic vessels; no direct PH‑MK‑polyamine studies.
- *Evidence status:* **Direct** for MK enzyme; **indirect** for PASMC mitogenic effect; **speculative** for MK‑derived polyamines driving PH vascular remodeling.

**Predicted observations:**
- *In MKs:* Elevated AMD1 and polyamines.
- *In tissue:* Perivascular polyamine gradient; increased proliferation in PASMCs adjacent to MK‑rich areas.
- *In metabolomics:* Whole‑lung spermidine/spermine elevated in PH.

**Experimental validation:**
- *Perturbation:* MK‑specific *Amd1* KO.
- *Model:* PF4‑Cre × *Amd1*^fl/fl hypoxia.
- *Readout:* PASMC proliferation (EdU incorporation), medial thickness (Media/CSA), and polyamine tissue content.
- *Expected result:* KO reduces PASMC proliferation independent of immune changes.
- *Falsifying result:* No reduction in PASMC proliferation or muscularization despite lowered polyamines.

**Novelty:** Directly implicates MK‑derived polyamines as a novel mitogenic signal for vascular smooth muscle in PH.
**Weaknesses:** Unclear polyamine bioavailability; no receptor-level link; proximity assumption.

**Priority estimate:**
- Directional specificity: 3
- Data support: 4
- Literature support: 3
- Novelty: 5
- Testability: 4
- **Overall: 4**

---

### Hypothesis ID: Axis3_AMD1_EV
**Hypothesis title:** MK AMD1‑driven polyamine production is exported via extracellular vesicles to activate adventitial fibroblasts and promote ECM remodeling.
**PI instruction addressed:** Candidate‑axis validation for Evo_H1, EV/stromal route.
**Core directional hypothesis:** Hypoxic MKs upregulate AMD1, load polyamines into extracellular vesicles, and deliver them to fibroblasts, driving collagen deposition and vascular stiffness.
**Direction‑level reasoning summary:**
- **Data anchor:** Methionine‑AMD1 axis as before.
- **Biological interpretation:** MKs are prolific EV producers, and metabolites can be selectively packaged into EVs under stress; polyamine‑rich EVs could act as stromal‑remodeling signals.
- **MK‑linked pathway logic:** AMD1 overactivity increases polyamine pool; if EV biogenesis genes (*Rab27a*, *Tsg101*) are MK‑expressed (pending mandatory check), polyamine loading into EVs is biophysically plausible.
- **Candidate downstream axis:** **EV/stromal** (fibroblast activation, ECM crosslinking).
- **Remodeling logic:** Fibroblast activation and collagen/LOX deposition stiffen the vessel wall, contributing to sustained PH.
- **Key uncertainty:** Whether polyamines are selectively loaded into MK‑derived EVs under hypoxia, and whether fibroblasts are the primary recipients; also requires confirmation of EV‑biogenesis gene expression.

**Directional chain:**
1. Hypoxia → MK *Amd1* ↑ → polyamine overproduction.
2. Polyamines are packaged into extracellular vesicles (exosomes/microvesicles) via mechanisms involving Rab27a/Tsg101 (if expressed).
3. Broad downstream axis: **EV/stromal** — EV‑delivered polyamines activate adventitial fibroblasts, upregulating LOX/LOXL and collagen synthesis.
4. Fibroblast differentiation and ECM remodeling → vessel wall stiffening.
5. Contributes to reduced compliance and fixed pulmonary hypertension.

**Candidate downstream axes:**
- *Plausible axes:* EV/stromal, direct vascular‑wall, immune‑mediated.
- *Working model (provisional):* EV‑mediated fibroblast activation.
- *Specific examples (candidate):* Spermidine in EVs may hypusinate eIF5A in fibroblasts, boosting collagen translation; not settled.
- *MK‑origin gap:* Evidence that MK‑EVs contain polyamines and that *Rab27a/Tsg101* are MK‑enriched (mandatory check pending).
- *Falsification:* Conditional *Amd1* KO should reduce polyamine content in lung‑derived EVs and blunt fibroblast activation markers; if EV cargo changes but fibroblast readouts are unchanged, EV‑stromal axis is disfavored.

**Evidence basis:**
- *User‑provided data:* AMD1 differential; EV gene expression not yet available.
- *Public dataset analysis:* None specific.
- *Literature:* General concept of metabolite‑containing EVs; no MK‑EV‑polyamine‑fibroblast axis reported.
- *Evidence status:* **Speculative**; requires confirmation of EV‑gene expression and polyamine EV loading.

**Predicted observations:**
- *In MKs:* Elevated AMD1 and EV‑associated polyamines.
- *In tissue:* Fibroblast activation (α‑SMA, collagen I) near MKs; polyamine‑positive EVs in the perivascular space.
- *In metabolomics:* EV fractions from BALF or lung tissue enriched for spermidine/spermine.

**Experimental validation:**
- *Perturbation:* MK‑specific *Amd1* KO.
- *Model:* PF4‑Cre × *Amd1*^fl/fl hypoxia; isolate lung‑derived EVs.
- *Readout:* EV polyamine mass spectrometry, fibroblast activation markers (Loxl2, Col1a1), and vascular stiffness (pressure‑volume loops).
- *Expected result:* *Amd1* KO reduces polyamine‑positive EVs and attenuates fibroblast activation and stiffness.
- *Falsifying result:* Fibroblast markers unchanged despite altered EV polyamines, or EV biogenesis genes not MK‑dependent.

**Novelty:** Proposes metabolite‑loaded MK‑EVs as intercellular signals that modulate vascular wall composition.
**Weaknesses:** Entirely speculative without EV gene data; lacks proof of polyamine‑EV association.

**Priority estimate:**
- Directional specificity: 3
- Data support: 2 (pending EV gene check)
- Literature support: 2
- Novelty: 5
- Testability: 3 (requires EV isolation)
- **Overall: 2 (upgrade pending mandatory EV gene results)**

---

### Hypothesis ID: Axis4_Inosine_immune
**Hypothesis title:** MK inosine release fuels extracellular adenosine that skews perivascular immune responses toward a pro‑remodeling state.
**PI instruction addressed:** Candidate‑axis validation for Evo_H2 (MK‑Pnp‑inosine/adenosine), immune‑mediated route.
**Core directional hypothesis:** Hypoxic MKs upregulate *Pnp* and release inosine; locally generated adenosine modulates T‑cell/macrophage phenotypes, promoting vascular inflammation and muscularization.
**Direction‑level reasoning summary:**
- **Data anchor:** Inosine is elevated in PH‑CD41⁺ MKs (log2FC 3.82, sFig6A); *Pnp* (direct compound‑enzyme) shows significant PH‑up in MKs (log2FC 1.739, p = 3.81 × 10⁻⁶, Seurat) despite modest baseline enrichment.
- **Biological interpretation:** Inosine accumulation reflects hypoxia‑enhanced purine catabolism; it can serve as a precursor for extracellular adenosine, a powerful immunomodulator.
- **MK‑linked pathway logic:** Pnp (purine nucleoside phosphorylase) is a direct enzyme for inosine; MK‑derived inosine may be exported and sequentially metabolized by ecto‑enzymes or neighbouring cells to adenosine.
- **Candidate downstream axis:** **Immune‑mediated** (adenosine receptor signaling on T cells, macrophages, or dendritic cells).
- **Remodeling logic:** Adenosine can promote a pro‑fibrotic/Th2‑like microenvironment that drives smooth muscle cell activation and muscularization.
- **Key uncertainty:** Whether MK‑derived inosine is quantitatively important as an adenosine precursor in the lung, and whether adenosine’s net effect is pro‑remodeling in this context.

**Directional chain:**
1. Hypoxia upregulates *Pnp* and nucleotide metabolism in lung MKs, leading to inosine accumulation.
2. MKs release inosine into the interstitial space.
3. Inosine is taken up by neighbouring cells and converted to adenosine (via salvage pathways and ecto‑nucleotidases), activating adenosine receptors. Broad downstream axis: **Immune‑mediated** — adenosine binds A2A/A2B receptors on T cells and macrophages, altering cytokine profiles.
4. Immune shift (e.g., enhanced Th17 or impaired Treg) fosters chronic perivascular inflammation.
5. Contributes to muscularization and vascular stiffening.

**Candidate downstream axes:**
- *Plausible axes:* Immune‑mediated, direct vascular‑wall, EV/stromal.
- *Working model (provisional):* Adenosine‑mediated immune modulation.
- *Specific examples (candidate):* Adenosine A2B receptor engagement on T cells could promote IL‑17 production; not settled.
- *MK‑origin gap:* Proof that MK‑released inosine is the dominant source of perivascular adenosine; receptor subtype specificity unknown.
- *Falsification:* Conditional *Pnp* KO in MKs (Pf4‑Cre) should lower lung adenosine and alter perivascular immune cell phenotypes; if an adenosine receptor antagonist (e.g., A2B blocker) does not reverse muscularization, the immune axis is unlikely.

**Evidence basis:**
- *User‑provided data:* Inosine up in PH MKs; *Pnp* PH‑up in MK scRNA‑seq.
- *Public dataset analysis:* GSE289322 DE output could test if *Pnp* and purine metabolism genes are upregulated in whole lung PH (**awaiting review**). Positive result would strengthen tissue‑level link.
- *Literature:* Extracellular adenosine is known to modulate pulmonary inflammation; inosine can be converted to adenosine via salvage kinases, but no direct MK‑to‑immune PH studies.
- *Evidence status:* **Direct** for MK inosine/Pnp; **indirect** for adenosine formation; **speculative** for immune‑mediated remodeling.

**Predicted observations:**
- *In MKs:* Elevated Pnp protein and inosine export.
- *In recipient tissue:* Increased adenosine concentration in lung interstitium near MKs; adenosine receptor activation markers (e.g., cAMP) in immune cells.
- *In metabolomics:* Whole‑lung inosine/adenosine levels correlate with MK numbers.

**Experimental validation:**
- *Perturbation:* MK‑specific *Pnp* knockout (Pf4‑Cre × *Pnp*^fl/fl).
- *Model:* Hypoxia, 3 wk.
- *Readout:* Lung adenosine (microdialysis or homogenate), immune cell flow cytometry (Th17, Treg, macrophages), and muscularization.
- *Expected result:* *Pnp* KO reduces local adenosine, shifts immune profile (e.g., fewer IL‑17⁺ cells), and attenuates remodeling.
- *Falsifying result:* No change in adenosine or immune composition despite reduced MK inosine.

**Novelty:** Identifies MKs as a source of inosine that feeds an adenosine‑driven immunomodulatory loop in PH.
**Weaknesses:** Indirect inosine‑to‑adenosine conversion; adenosine’s effects are pleiotropic; receptor‑blocker experiments may not assign origin.

**Priority estimate:**
- Directional specificity: 3
- Data support: 4
- Literature support: 3
- Novelty: 5
- Testability: 4
- **Overall: 4**

---

### Hypothesis ID: Axis5_Inosine_vascular
**Hypothesis title:** MK‑derived inosine supplies purine precursors that directly fuel proliferation of pulmonary vascular cells.
**PI instruction addressed:** Candidate‑axis validation for Evo_H2, direct vascular‑wall route.
**Core directional hypothesis:** Hypoxic lung MKs release inosine, which is taken up by endothelial and smooth muscle cells via nucleoside transporters, incorporated into nucleotide synthesis, and supports cell cycle progression and medial muscularization.
**Direction‑level reasoning summary:**
- **Data anchor:** Inosine‑Pnp axis as above.
- **Biological interpretation:** Rapidly dividing cells require increased purine nucleotides; inosine can be salvaged to IMP and then ATP/GTP; MK‑derived inosine could be a metabolic substrate for PASMCs.
- **MK‑linked pathway logic:** Pnp controls inosine levels; MKs positioned near the vessel wall could supply inosine directly to proliferating vascular cells.
- **Candidate downstream axis:** **Direct vascular‑wall** (nucleoside salvage and adenosine receptor‑mediated proliferation).
- **Remodeling logic:** Enhanced nucleotide availability promotes PASMC hyperplasia and endothelial dysfunction, leading to medial hypertrophy.
- **Key uncertainty:** Whether inosine uptake is rate‑limiting for PASMC proliferation under hypoxia, as opposed to canonical growth factor signals.

**Directional chain:**
1. Hypoxic MKs upregulate *Pnp* and release inosine.
2. Inosine is transported into endothelial cells and PASMCs via equilibrative nucleoside transporters (ENT1/2).
3. Inside vascular cells, inosine is phosphorylated to IMP, channeled into ATP synthesis and DNA replication; additionally, intracellular adenosine derived from inosine can activate pro‑proliferative A2B receptors. Broad downstream axis: **Direct vascular‑wall**.
4. PASMC and endothelial proliferation → medial thickening and muscularization.
5. Contributes to increased pulmonary vascular resistance.

**Candidate downstream axes:**
- *Plausible axes:* Direct vascular‑wall, immune‑mediated.
- *Working model (provisional):* Inosine as an anabolic fuel for vascular cell growth.
- *Specific examples (candidate):* Inosine entering the salvage pathway provides ribose‑1‑phosphate and purine bases; adenosine A2B‑cAMP‑PKA upregulates cyclin D1; not settled.
- *MK‑origin gap:* Quantitative contribution of MK inosine relative to endogenous purine synthesis in vascular cells.
- *Falsification:* Conditional *Pnp* KO in MKs should reduce PASMC proliferation, measurable by Ki67⁺ cells in media, and should be rescued by exogenous inosine infusion. If KO does not reduce proliferation, direct metabolic support axis is unlikely.

**Evidence basis:**
- *User‑provided data:* As above.
- *Public dataset analysis:* GSE289322 may show upregulation of nucleoside transporters and purine metabolism genes in whole lung PH. **Awaiting review.**
- *Literature:* Nucleoside salvage supports cancer cell proliferation; adenosine receptors are known to promote PASMC growth in some contexts.
- *Evidence status:* **Indirect**; MK‑derived inosine as a quantitative precursor for vascular cells is speculative.

**Predicted observations:**
- *In MKs:* Inosine release detectable in conditioned media.
- *In recipient tissue:* Increased ^13C‑inosine incorporation into PASMC nucleotides after isotope tracing in PH lungs.
- *In metabolomics:* Lung tissue inosine turnover elevated in PH.

**Experimental validation:**
- *Perturbation:* MK‑specific *Pnp* KO plus ^13C‑inosine infusion.
- *Model:* PF4‑Cre × *Pnp*^fl/fl, hypoxia.
- *Readout:* Nucleotide labeling (LC‑MS) in isolated PASMCs, proliferation (EdU/Ki67), muscularization.
- *Expected result:* KO blunts inosine incorporation into vascular nucleotides and reduces PASMC proliferation, which is rescued by exogenous inosine.
- *Falsifying result:* No change in PASMC proliferation or nucleotide labeling, even with inosine supplementation.

**Novelty:** Proposes MK‑derived inosine as a direct anabolic contributor to vascular cell proliferation.
**Weaknesses:** Does not account for redundancy with other purine sources; salvage pathway may not be limiting.

**Priority estimate:**
- Directional specificity: 3
- Data support: 3
- Literature support: 3
- Novelty: 5
- Testability: 3 (requires isotope tracing)
- **Overall: 3**

---

### Hypothesis ID: Axis6_Matricellular_exploratory
**Hypothesis title:** *(Pending mandatory Seurat verification)* MK matricellular/coagulation/EV secretome axis drives vascular remodeling via thrombospondin‑1, tissue factor, PDGF‑B, and TGF‑β1.
**PI instruction addressed:** Revive MK matricellular/coagulation/EV secretome hypothesis only after mandatory Seurat queries confirm MK enrichment and hypoxia‑up of *Thbs1, F3, Pdgfb, Tgfb1*.
**Core directional hypothesis:** If *Thbs1, F3, Pdgfb, Tgfb1* are MK‑enriched and hypoxia‑induced, then hypoxic MKs orchestrate a pro‑remodeling secretome that activates perivascular cells, promotes coagulation/inflammation, and drives muscularization and endothelial dysfunction.
**Direction‑level reasoning summary:**
- **Data anchor:** **Mandatory Seurat gene expression results pending.** If positive, protein products of these genes are known to influence ECM (TSP‑1, TGF‑β), coagulation (TF), and vascular cell recruitment (PDGF‑B).
- **Biological interpretation:** Coordinated upregulation of a matricellular/coagulation program in MKs would mirror a hypoxia‑activated secretome that directly modifies the vessel wall.
- **MK‑linked pathway logic:** MKs are known to store and release TSP‑1 and TGF‑β1 in platelet‑like modes; lung‑resident MKs may secrete these factors locally.
- **Candidate downstream axis:** **Immune‑mediated and direct vascular‑wall** (TSP‑1 activates TGF‑β, recruits inflammatory cells; TF triggers thrombin/PAR signaling; PDGF‑B stimulates PASMC growth).
- **Remodeling logic:** Multifactorial secretome could induce smooth muscle hyperplasia, endothelial‑to‑mesenchymal transition (candidate example), and perivascular fibrosis.
- **Key uncertainty:** The mandatory Seurat results are not yet available; without them the hypothesis is unsupported.

**Directional chain:**
1. Hypoxia upregulates *Thbs1*, *F3*, *Pdgfb*, *Tgfb1* in lung MKs (to be confirmed).
2. MKs secrete TSP‑1, TF, PDGF‑B, and TGF‑β1 into the perivascular space.
3. Broad downstream axes: Direct vascular‑wall (TGF‑β/PARP signaling in PASMCs; PDGF‑B mitogenicity), immune‑mediated (TSP‑1 activating latent TGF‑β and recruiting monocytes), and coagulation‑inflammatory (TF‑thrombin‑PAR1 axis).
4. Combined effects drive smooth muscle proliferation, endothelial dysfunction, and ECM deposition.
5. Contributes to florid muscularization, medial thickening, and possibly thrombosis in situ.

**Candidate downstream axes:**
- *Plausible axes:* Direct vascular‑wall, immune‑mediated, coagulation/thrombo‑inflammatory.
- *Working model (provisional):* TSP‑1‑driven TGF‑β activation as a dominant effector.
- *Specific examples (candidate):* TGF‑β1 can induce EndMT or PASMC differentiation; TF may generate thrombin that activates PAR‑1 on vascular cells. Not settled.
- *MK‑origin gap:* Expression proof required; if any of the genes are not MK‑enriched/PH‑up, the hypothesis must be pruned.
- *Falsification:* Conditional knockout of *Thbs1* in MKs (Pf4‑Cre) should reduce active TGF‑β in lung and attenuate muscularization; if not, the axis is not driven by MK TSP‑1.

**Evidence basis:**
- *User‑provided data:* **Mandatory Seurat query results missing; gene expression unknown.**
- *Public dataset analysis:* GSE289322 may provide whole‑lung expression of these genes; if they are coordinately upregulated, that would support tissue impact. **Awaiting DE review.**
- *Literature:* TSP‑1 is a well‑characterized activator of latent TGF‑β; TF and PDGF‑B are established vascular remodeling factors; MK/platelet stores are known.
- *Evidence status:* **Currently unsupported** until mandatory Seurat results are obtained; if positive, evidence becomes direct for MK expression, indirect for functional secretion.

**Predicted observations:** (conditional on positive Seurat)
- *In MKs:* Increased TSP‑1, TF, PDGF‑B, TGF‑β1 mRNA and protein under hypoxia.
- *In tissue:* Elevated active TGF‑β, thrombin‑antithrombin complexes, and PDGF‑BB near MK‑rich regions.
- *In pathway activity:* SMAD2/3 phosphorylation in PASMCs and perivascular cells.

**Experimental validation:**
- *Perturbation:* Conditional KO of *Thbs1* or *F3* in MKs (individually or combined).
- *Model:* PF4‑Cre, hypoxia.
- *Readout:* TGF‑β activity (pSMAD2 staining), coagulation markers, cellular proliferation, and muscularization.
- *Expected result:* KO of a key matricellular factor reduces downstream activators and remodeling.
- *Falsifying result:* No change in remodeling, suggesting redundancy or non‑MK sources dominate.

**Novelty:** Re‑frames MKs as local orchestrators of a pro‑fibrotic and pro‑coagulative niche in PH.
**Weaknesses:** Entirely dependent on yet‑unperformed Seurat queries; likely many of these factors can also come from platelets, so conditional KO must be MK‑specific.

**Priority estimate (contingent):**
- Directional specificity: 4
- Data support: **0 (pending)**
- Literature support: 4
- Novelty: 4
- Testability: 4
- **Overall: *Not generated until mandatory Seurat results confirm; if positive, rank high.***

---

**Self‑filtered rejected ideas:**
- *Amd2* or *Dnmt3b* chains: lower readiness scores (30 and 15.6), modest MK enrichment, or non‑significant PH shift; not selected to avoid redundancy with stronger Amd1 axis.
- *Retinoic acid/Cyp26b1* chain: no significant differential expression (p = 0.253), low readiness (14); insufficient evidence for a direction‑level hypothesis.
- Any hypothesis lacking a direct metabolite‑enzyme‑MK loop (e.g., purely literature‑based) was excluded.
- Matricellular/EV hypotheses that assumed MK enrichment of *Thbs1*, *F3*, etc. without evidence were excluded, except the explicitly pending Axis6.

**Requests for Tool Use Agent:**
1. Provide the completed GSE289322 differential expression statistics and GSEA results for the candidate gene set and pathways listed in the PI brief (polyamine, purine, coagulation, TGF‑β, ECM).  
2. Perform mandatory Seurat queries in `seurat_merged.rds` for *Pdgfb, Tgfb1, F3, Thbs1, Glo1, Rab27a, Tsg101, Cd44, Lox, Loxl1, Loxl2, Mki67* and append the results to the cycle evidence base.  
3. If any of the above genes show positive MK enrichment and PH‑up shift, flag Axis6 as ready for immediate validation planning.  
4. If *Glo1* shows MK‑specific downregulation and methylglyoxal is elevated in metabolomics, flag a potential new methylglyoxal‑MK axis.
